STAT
DECEMBER 14, 2022
Hospice in America is gravely ill. An extensive investigation jointly published by The New Yorker and ProPublica documented outright fraud, predatory practices, and flagrant mistreatment by specific publicly traded and private equity-owned hospice companies.
PharmaVoice
DECEMBER 13, 2022
As new and advanced therapies are revealed at the annual meeting of the American Society of Hematology this week, the patients are always at the center.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 11, 2022
Digital transformation in pharma is not a singular endeavour. It can mean everything from patient-facing disease management apps and wearables to background AI dramatically altering drug discovery or radiological imaging. So, when a life sciences company embarks on a project of digital transformation or innovation, it’s really embarking on multiple projects that span the wide world of pharmaceutical operations.
PhRMA
DECEMBER 15, 2022
Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group (BRG) found that nearly 36% of all Medicare Part B therapy sales occurred at 340B hospitals in 2021 , up nearly 17 percentage points since 2012, meaning care is moving from physician offices and non-340B hospitals to 340B hospitals.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
DECEMBER 13, 2022
An experimental cancer vaccine being developed by the biotechnology firm Moderna and the drug giant Merck reduced the risk that melanoma would return after surgery or that patients would die by 44%, the company said. The data, made public in a press release, represent the first evidence of an effective individualized cancer vaccine based on mRNA, the technology used in the Covid shots.
PharmaVoice
DECEMBER 16, 2022
A breakdown of how Twitter’s recent shifts are impacting pharma, and how the industry should navigate the platform in 2023.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
PharmExec
DECEMBER 14, 2022
Perspectives from a board member and an aspiring board member on how to increase the number of qualified women on boards.
STAT
DECEMBER 12, 2022
This Wednesday will mark two years since nurse Sandra Lindsay became the first person in the U.S. to receive a Covid-19 vaccine outside of a clinical trial. A study released Tuesday by the Commonwealth Fund shows that in those two years, the Covid vaccines have averted over 3 million deaths in the U.S. The Centers for Disease Control and Prevention estimates that more than 1 million Americans have died from Covid-19 since the onset of the pandemic.
PharmaVoice
DECEMBER 12, 2022
A recent report ranks the top 20 pharma companies by how well they’re boosting a critical component of health equity.
European Pharmaceutical Review
DECEMBER 14, 2022
Moderna, Inc. and Merck have announced that a Phase IIb trial ( NCT03897881 ) of a personalised mRNA cancer vaccine (mRNA-4157/V940), in combination with KEYTRUDA ® , Merck’s anti-PD-1 therapy, demonstrated the first randomised evidence that a personalised neoantigen approach may be beneficial in treating melanoma. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA ® reduced the risk of recurrence or death by 44 percent (HR=0.56 [95 percent CI, 0.31-1.08]; one-sided p-valu
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Mirror
DECEMBER 16, 2022
The COVID-19 pandemic challenged researchers to discover life-saving treatments at an unprecedented pace. While these researchers rose to the occasion by discovering drugs faster than ever before, variants continue to challenge the world in addressing COVID-19. New innovations in computer-aided drug discovery tools could dramatically accelerate the study of new variants.
STAT
DECEMBER 14, 2022
Almost 90% of the health care companies deemed to be under financial stress by a leading credit rating agency are owned by private equity , a stark indicator of the toll financial investors have taken on a vital sector. The striking finding is part of a new Moody’s Investors Service report released this week that shows broad turbulence throughout an industry weakened by private equity’s practice of loading companies with debt, making them less resilient to challenges like Covid-19,
PharmaVoice
DECEMBER 12, 2022
Learn why an informed, holistic view is needed to succeed in today’s complex and dynamic landscape.
Compounding Pharmacy of America
DECEMBER 15, 2022
Semaglutide is highly effective as a weight loss drug, but it is not ideal for every situation. Powerful fat-burning alternatives can achieve similar results. The post Alternatives to Semaglutide for Weight Loss appeared first on The Compounding Pharmacy of America.
Pharmaceutical Technology
DECEMBER 12, 2022
Pipeline therapies within the cardiometabolic space have recently gathered interest following the 20th World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) Hybrid Conference, which took place on 1–3 December. The spotlight was placed on many up-and-coming pharmacotherapies within the space, one of which was Amgen’s obesity therapy, AMG-133, following the company’s announcement of its Phase I therapy results last week, on 1 December.
STAT
DECEMBER 10, 2022
Whenever a hematopoietic cell transplant patient tries to get a family member to sneak food in past the nurses, Federico Stella, a resident hematologist at the University of Milan, remembers. One was a girl who tried to get her sister to bring her a panettone, a Milanese sweet bread usually eaten around the holidays. A week before Christmas, the sister tried to hide the panettone in a bag.
PharmaVoice
DECEMBER 12, 2022
Here’s a look at how industry leaders are navigating the key issues of 2023.
Med Ed 101
DECEMBER 11, 2022
There are a number of medications that can be used for urge urinary incontinence, also known as “overactive bladder syndrome”. However, it can be somewhat difficult to parse out the differences between the medications and decide which might be the right choice for a patient. Today, we’ll be taking a closer look at the urinary […]. The post Urinary Anticholinergics Comparison Table appeared first on Med Ed 101.
Pharmaceutical Technology
DECEMBER 12, 2022
Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. The alliance will utilise the capabilities of both firms, including international cell therapy leadership and manufacturing of Kite.
STAT
DECEMBER 10, 2022
NEW ORLEANS — An emerging class of genetically targeted drugs is inducing remissions in about one-third of patients with advanced leukemia, according to updates Saturday from separate clinical trials. Two biotechs — Syndax Pharmaceuticals and Kura Oncology — are developing their own versions of so-called menin inhibitors that have the potential to become effective treatments for certain types of genetically defined acute myeloid leukemia (AML), a rapidly progressing bone mar
PharmaVoice
DECEMBER 15, 2022
Steve Quake, science head at the Chan Zuckerberg Initiative, is leveraging personal experiences and a deep background in R&D to lead an ambitious 100-year plan.
European Pharmaceutical Review
DECEMBER 12, 2022
The Scottish Medicines Consortium (SMC) has accepted Utrogestan, the only adjunctive micronised progesterone available as hormone replacement therapy (HRT) for use alongside any oestrogen-only HRT for women with an intact uterus. Utrogestan 100mg, a product by Besins Healthcare UK, is a body-identical hormone, which means it has the same molecular structure as the hormone produced by the body.
PhRMA
DECEMBER 14, 2022
A survey of more than 5,000 Americans conducted with Ipsos found that insured Americans want better health care coverage. These insights come from the third installment of the Patient Experience Survey and show how Americans favor policy solutions that improve their ability to navigate and access their care by seeking to remove barriers imposed by insurers and middlemen such as pharmacy benefit managers (PBMs).
STAT
DECEMBER 13, 2022
Open the website of Workit Health, and the path to treatment starts with a simple intake form: Are you in danger of harming yourself or others? If not, what’s your current opioid and alcohol use? How much methadone do you use? Within minutes, patients looking for online treatment for opioid use and other addictions can complete the assessment and book a video visit with a provider licensed to prescribe suboxone and other drugs.
pharmaphorum
DECEMBER 15, 2022
Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim’s Ofev, following new guidance from health technology assessment agency NICE. Ofev (nintedanib) has been recommended since 2015 for NHS use in IPF patients who have a forced vital capacity (FVC) value of 50% to 80% of normal, but will now be an option for people with less severe disease, i.e. an FVC of more than 80%.
European Pharmaceutical Review
DECEMBER 12, 2022
The Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted a licence extension for FORXIGA (dapagliflozin) in Great Britain for symptomatic chronic heart failure (HF) across the full spectrum of left ventricular ejection fraction (LVEF). The approval means potentially a further 250,000 patients across the full spectrum of LVEF >40 percent, including HF with reduced, mildly reduced, and preserved ejection fraction (HFrEF, HFmrEF, HFpEF) will be eligible for treatment in Engl
Pharmaceutical Technology
DECEMBER 15, 2022
Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments. Under the deal, the parties intend to develop treatments for diseases including Alzheimer’s and Parkinson’s. The alliance will merge the capabilities of the scientists at Washington University in the basic and clinical research in neurodegenerative ailments, such as dementia, with the wide-ranging expert
STAT
DECEMBER 12, 2022
Type “Ehlers-Danlos syndromes” into a search engine, and multiple suggestions pop up. Is Ehlers-Danlos an autoimmune disease? Is EDS hereditary? Rare? Then, the algorithm might suggest: Is Ehlers-Danlos syndrome a disease?
pharmaphorum
DECEMBER 14, 2022
Two virtual reality startups operating in the health category – BehaVR and OxfordVR – have agreed to pool their efforts on the development of digital therapeutics (DTx) for mental illnesses via a merger. The combined company will operate under the BehaVR brand, and starts operations with a $13 million cash injection from a Series B financing led by Oxford Science Enterprises and Optum Ventures with participation from Confluent Health, Accenture Ventures, Chrysalis Ventures, and Thornton Capital.
European Pharmaceutical Review
DECEMBER 13, 2022
North American psychedelic drug developers Mindset, PharmAla, Mydecine and Psyence have signed with clinical research organisation (CRO) Clerkenwell Health to trial therapies for mental health conditions, in London, UK, to benefit from the country’s swift drug regulatory process. The mental health conditions that the companies aim to treat include social anxiety, Autism Spectrum Disorder (ASD), nicotine addiction, major depressive disorder (MDD), and Adjustment Disorder in those facing a termina
Digital Pharmacist
DECEMBER 15, 2022
The role of pharmacies is somewhat changed compared to one in the past. People used to consider the pharmacy as a place to fill their prescriptions, but, pharmacies and pharmacists do much more than prepare medications. Most people fill their medication and medicinal devices from their local community pharmacies. To outstand and succeed among the other pharmacies, community pharmacies should find a way to distinguish their pharmacy from others.
STAT
DECEMBER 16, 2022
My grandmother died in the hospital, alone, the day after she was “found down” at home by emergency medical services. I lived near my Nani, as I called her but, even though I am a physician, was not allowed to see her after she had been admitted to her local hospital because of the strict, Covid-related no-visitor policy. I spent most of the evening sitting in my car in the hospital parking lot, paralyzed.
pharmaphorum
DECEMBER 12, 2022
In a fresh update, Bloomberg has reported that US biotech Amgen Inc. has agreed to purchase Dublin-based Horizon Therapeutics Plc. for €24.7 billion ($26bn), in a deal which could yet see further delays or a breakdown in negotiations. Following Sanofi’s withdrawal from the running, stating that “transaction price expectations do not meet [their] value creation criteria” – for the purposes of Rule 2.12 of the Irish Takeover Rules in response to Horizon’s announcement under Rule 2.4 of the I
The Guardian - Pharmaceutical Industry
DECEMBER 15, 2022
At least 19 children have died and scarlet fever cases are more than treble what they were in previous high season Three more children have died from strep A, it has emerged, and pharmacists in the UK have been told they can supply alternative antibiotics to those originally prescribed, in a bid to ease shortages of certain forms of penicillin. The UK Health Security Agency (UKHSA) data shows at least 19 children have now died across the UK, while there are 7,750 cases of scarlet fever so far th
Drug Channels
DECEMBER 12, 2022
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. Click here to see the original post and comments from September 2022. During Friday’s webinar, I’ll be sharing my updated thoughts about the IRA’s impact on manufacturers, Part D plans, and patient behavior. By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. 117-169).
Expert insights. Personalized for you.
363 
Let's personalize your content